Neoadjuvant FOLFIRINOX for Patients with Borderline Resectable or Locally Advanced Pancreatic Cancer: Results of a Decision Analysis

BACKGROUND. The effectiveness and cost‐effectiveness of using neoadjuvant FOLFIRINOX (nFOLFIRINOX) for patients with borderline resectable or locally advanced pancreatic ductal adenocarcinoma (BR/LA PDAC) are unknown. Our objective was to determine whether nFOLFIRINOX is more effective or cost‐effec...

Descripción completa

Detalles Bibliográficos
Autores principales: Choi, Jin G., Nipp, Ryan D., Tramontano, Angela, Ali, Ayman, Zhan, Tiannan, Pandharipande, Pari, Dowling, Emily C., Ferrone, Cristina R., Hong, Theodore S., Schrag, Deborah, Fernandez‐Del Castillo, Carlos, Ryan, David P., Kong, Chung Yin, Hur, Chin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2018
Materias:
Health Outcomes and Economics of Cancer Care
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6656457/
https://www.ncbi.nlm.nih.gov/pubmed/30559125
http://dx.doi.org/10.1634/theoncologist.2018-0114

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6656457/
https://www.ncbi.nlm.nih.gov/pubmed/30559125
http://dx.doi.org/10.1634/theoncologist.2018-0114

Ejemplares similares